| Autor: |
Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Drugs in Context, Pp 1-8 (2016) |
| Druh dokumentu: |
article |
| ISSN: |
1740-4398 |
| DOI: |
10.7573/dic.212301 |
| Popis: |
Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), AOM 400 demonstrated greater improvement in health-related quality of life and functioning in patients with stable schizophrenia. The present analysis used health economics assessment data collected during the QUALIFY study to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months. Compared with those receiving PP, patients receiving AOM 400 incurred significantly lower direct total costs ($8908±186 vs $9675±190, p=0.005) and treatment costs ($7967±113 vs $8706±116, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
